Atyr PHARMA’s (ATYR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $35.00 price objective on the stock.

ATYR has been the subject of several other research reports. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Leerink Partners initiated coverage on Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 target price for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Price Performance

ATYR opened at $5.38 on Wednesday. Atyr PHARMA has a 12-month low of $1.42 and a 12-month high of $5.75. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The business’s fifty day simple moving average is $3.49 and its 200-day simple moving average is $3.52. The company has a market capitalization of $478.84 million, a price-to-earnings ratio of -5.72 and a beta of 0.88.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. On average, equities research analysts anticipate that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Group One Trading LLC purchased a new stake in Atyr PHARMA during the fourth quarter valued at approximately $26,000. Victory Capital Management Inc. acquired a new position in shares of Atyr PHARMA during the fourth quarter worth $37,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Atyr PHARMA during the first quarter worth $38,000. Raymond James Financial Inc. purchased a new stake in shares of Atyr PHARMA during the 4th quarter valued at $39,000. Finally, XTX Topco Ltd acquired a new stake in shares of Atyr PHARMA in the 4th quarter worth $40,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.